GVL effect in plasmacytoid DC leukemia/lymphoma

Bone Marrow Transplantation

Volumn 45, Issue 5, 2010, Pages 961-962

  Kaloyannidis, P ^a   Zomas, A ^b   Paterakis, G ^c   Vadikoliou, C ^a   Mallouri, D ^a   Sakkas, L ^a   Sakellari, I ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CD123 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD56 ANTIGEN; CD64 ANTIGEN; CD68 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DECTIN 2; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HLA DR ANTIGEN; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROPILIN 1; PROTEOGLYCAN; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER REGRESSION; CASE REPORT; CHROMOSOME 13Q; CHROMOSOME 21Q; CHROMOSOME ANALYSIS; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPHENOTYPING; LETTER; MALE; PLASMACYTOID DENDRITIC CELL LEUKEMIA; PLASMACYTOID DENDRITIC CELL LYMPHOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME;

DENDRITIC CELLS; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77952430644     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.270     Document Type: Letter

References (9)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. WHO-EORTC classification for cutaneus lymphomas. Blood 2005;105:3678-3685.
2. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol 2007;136:539-548.
3. Feuillard J, Jacob MC, Valenci F, Maynadiè M, Gressin R, Chaperot L et al. Clinical and biologic features of CD4+ CD 56+ malignancies. Blood 2002;99:1556-1563.
4. Reimer P, Rüdiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A et al. What is CD4+ CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003;32:637-646.
5. Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A et al. Donor lymphocyte Infusion in the treatment of first haematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukaemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007;25:4938-4945.
6. Ghaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001;97:3210-3217.
7. Chaperot L, Perrot I, Jacob MC, Blanchard D, Salaun V, Deneys V et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol 2004;34:418-426.
8. Hanabuchi S, Watanabe N, Wang YH, Wang YH, Ito T, Shaw J et al. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptorligand (GITRL). Blood 2006;107:3617-3623.
9. Naranjo-Gómez M, Oliva H, Climent N, Fernàndez MA, Ruiz-Riol M, Bofill M et al. Expression and function of IL-2 receptor in activated human plasmatoid dendritic cells. Eur J Immunol 2007;37:1764-1772.